Personalized AV-GBM-1 Vaccine Shows Promise for Aggressive Brain Cancer

Personalized AV-GBM-1 Vaccine Shows Promise for Aggressive Brain Cancer

282448

Personalized AV-GBM-1 Vaccine Shows Promise for Aggressive Brain Cancer

Adding AIVITA Biomedical’s experimental and personalized cancer vaccine, AV-GBM-1, to post-surgery standard treatment slows disease progression in adults newly diagnosed with glioblastoma — the most aggressive type of brain cancer — according to two-year data from a Phase 2 clinical trial. “The improvement in glioblastoma patients who were treated with AV-GBM-1, compared to studies with the standard of care, is a very promising indication that our therapy confers benefit to patients in need,” Robert O.…

You must be logged in to read/download the full post.